New drug cocktail aims to shrink Hard-to-Treat lung tumors
NCT ID NCT06512051
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called SHR-A2102 combined with the immunotherapy adebrelimab, with or without chemotherapy or bevacizumab, in 248 people with advanced or metastatic non-small cell lung cancer. The goal is to find the safest dose and see if the combination can shrink tumors. Participants must have measurable tumors and provide a tissue sample.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-A2102 (a targeted drug) combined with adebrelimab (an immunotherapy), plus possible chemotherapy or bevacizumab
What this could lead to
If successful, this could offer a new treatment option for people with advanced lung cancer that has stopped responding to other therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug combo may not work or could cause serious side effects. It is not yet proven to be safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese People's Liberation Army General Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact